Bang D
Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Med J. 1997 Dec;38(6):401-10. doi: 10.3349/ymj.1997.38.6.401.
Behçet's disease is characterized with multifactorial etiopathogenesis and multiclinical pictures. The treatment of patients with Behçet's disease is based on the severity of illness, and the most appropriate management of Behçet's disease requires a multidisciplinary approach. Although various therapeutic modalities have been employed for Behçet's disease, treatment is far from satisfactory. Treatment of Behçet's disease includes local, systemic, or surgical therapies. Limited success has been found with colchicine, azathioprine, indomethacin, cyclophosphamide, chlorambucil, levamisole, transfer factor, fibrinolytic therapy, and systemic corticosteroid. New therapeutic approaches have been introduced for Behçet's disease using cyclosporine, thalidomide, interferon, acyclovir, high-dose corticosteroids or cyclophosphamide pulse therapy, and FK 506. We suggest that therapeutic agents should be selected after thorough evaluation of the immune state of each patient by using various tests and by determining any aggravating or provoking factors involved. In general, a combination-agent regimen is more effective than a single-agent regimen. Early diagnosis and proper treatment can inhibit or at lease slow the progress of the disease remarkably.
白塞病具有多因素发病机制和多种临床表现。白塞病患者的治疗基于疾病的严重程度，而对白塞病最恰当的管理需要多学科方法。尽管已对白塞病采用了各种治疗方式，但治疗效果仍远不尽人意。白塞病的治疗包括局部、全身或手术治疗。秋水仙碱、硫唑嘌呤、吲哚美辛、环磷酰胺、苯丁酸氮芥、左旋咪唑、转移因子、纤维蛋白溶解疗法和全身用皮质类固醇的疗效有限。已对白塞病引入了新的治疗方法，使用环孢素、沙利度胺、干扰素、阿昔洛韦、大剂量皮质类固醇或环磷酰胺脉冲疗法以及他克莫司（FK 506）。我们建议，应通过使用各种检测方法全面评估每位患者的免疫状态并确定任何相关的加重或诱发因素后，再选择治疗药物。一般而言，联合用药方案比单一用药方案更有效。早期诊断和恰当治疗可显著抑制或至少减缓疾病的进展。
